Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 75

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Migraine

Not recruiting

Study of Rimegepant for Prevention of Menstrual Migraine in Women Aged 18-45 Years

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Parkinson's disease

Not recruiting

Comparing Skin Adhesiveness of a New Rotigotine 12 mg/24 h Transdermal Patch Versus Standard Treatment in Patients with Parkinson's Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rotigotine
  • Sponsor:Luye Pharma Switzerland AG

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Migraine

Not recruiting

Study on the Effects of Cilostazol on Headaches in Men and Women with Migraine Without Aura

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Cilostazol
  • Sponsor:Syddansk Universitet (University of Southern Denmark)

Glioblastoma+1

Not recruiting

Study on the Safety of Photodynamic Therapy with Aminolevulinic Acid Hydrochloride for Patients Aged 18-75 with Grade IV Glioblastoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Hemerion Therapeutics

Essential tremor

Not recruiting

Study on the Effectiveness of BP1.4979 for Adults with Essential Tremor

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Cognitive disorder+1

Not recruiting

Study on Metformin and Lifestyle Changes to Prevent Dementia in Older Adults at Risk

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Metformin Hydrochloride
  • Sponsor:Imperial College London Limited

Dementia Alzheimer's type

Not recruiting

Study of microglial activation and synaptic density using [18F]-DPA-714, [18F]-Ro948, [11C]-UCB-J, and [11C]PiB PET imaging in patients with Alzheimer's disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:(4R)-1-[(3-(11C)Methylpyridin-4-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)Pyrrolidin-2-One
  • Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Epileptic encephalopathy

Not recruiting

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

Parkinson's disease

Not recruiting

Study on the Expression of the 5-HT4 Receptor in Patients with Mild to Moderate Parkinson's Disease Using [C11]-SB207145

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:(1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE
  • Sponsor:Hospices Civils De Lyon

Progressive supranuclear palsy

Not recruiting

Study on Brain Imaging with [18F]PI-2620 for Progressive Supranuclear Palsy Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Izaflortaucipir (18F)
  • Sponsor:Clinica Universidad De Navarra

Nervous system disorder

Not recruiting

Study on the Effects of Cannabidiol on the Central Nervous System in Healthy Male Participants

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Cannabidiol
  • Sponsor:Centre for Human Drug Research

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.